MedTrace Logo

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

NCT03895229 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-04-02

No results posted yet for this study

Summary

An Open-label, One way, Two period Comparative study To Determine The effect of Morning Versus Evening administration of Empagliflozin 10mg on Its Pharmacokinetics And Pharmacodynamics in Healthy Adults

Conditions

Interventions

DRUG

Empagliflozin 10 MG Oral Tablet [Jardiance]

Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus

Sponsors & Collaborators

  • Drug Research Centre, Cairo, Egypt

    collaborator OTHER

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Rana M Ali, MD student · Ainshams University

  • Nagwa A Sabry, phD · Ainshams University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2018-10-19
Completion
2018-10-26

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03895229 on ClinicalTrials.gov